Stephanie Dramburg

Stephanie Dramburg

Auto-generated profile, based on publicly available information

Stephanie Dramburg

Charité–Universitätsmedizin Berlin, a corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2023 in Pediatric Allergy and Immunology
Verified
Journal Article
Open access
SDStephanie Dramburg
Stephanie Dramburg
Christiane HilgerChristiane Hilger
Christiane Hilger
ASAlexandra F Figueira Santos
Alexandra F Figueira Santos
LVLeticia de las Vecillas
Leticia de las Vecillas
RARob C. Aalberse
Rob C. Aalberse
KHKarin Hoffmann-Sommergruber
Karin Hoffmann-Sommergruber
Since the discovery of immunoglobulin E (IgE) as a mediator of allergic diseases in 1967, our knowledge about the immunological mechanisms of IgE‐mediated allergies has remarkably increased. In addition to understanding the immune response and clinical symptoms, allergy diagnosis and management depend strongly on the precise identification of the elicitors of the IgE‐mediated allergic reaction. In the past four decades, innovations in bioscience and technology have facilitated the identification and production of well‐defined, highly pure molecules for component‐resolved diagnosis (CRD), allowing a personalized diagnosis and management of the allergic disease for individual patients. The first edition of the “EAACI Molecular Allergology User's Guide” (MAUG) in 2016 rapidly became a key reference for clinicians, scientists, and interested readers with a background in allergology, immunology, biology, and medicine. Nevertheless, the field of molecular allergology is moving fast, and after 6 years, a new EAACI Taskforce was established to provide an updated document. The Molecular Allergology User's Guide 2.0 summarizes state‐of‐the‐art information on allergen molecules, their clinical relevance, and their application in diagnostic algorithms for clinical practice. It is designed for both, clinicians and scientists, guiding health care professionals through the overwhelming list of different allergen molecules available for testing. Further, it provides diagnostic algorithms on the clinical relevance of allergenic molecules and gives an overview of their biology, the basic mechanisms of test formats, and the application of tests to measure allergen exposure.

22 June 2019 in Allergy
Verified
Journal Article
Closed access
PDF file
PMPaolo Maria Matricardi
Paolo Maria Matricardi
SDStephanie Dramburg
Stephanie Dramburg
AAAlberto Alvarez‐Perea
Alberto Alvarez‐Perea
DADarío Antolín-Amérigo2
Darío Antolín-Amérigo2
CAChristian Apfelbacher
Christian Apfelbacher
IAIoana Agache
Ioana Agache

20 November 2023 in Allergy
Verified
Journal Article
Open access
Magdalena Zemelka-WiacekMagdalena Zemelka-Wiacek
Magdalena Zemelka-Wiacek
IAIoana Agache
Ioana Agache
CACezmi A. Akdis
Cezmi A. Akdis
MAMubeccel Akdis
Mubeccel Akdis
TCThomas B Casale
Thomas B Casale
Marek JutelMarek Jutel
Marek Jutel
The importance of allergen immunotherapy (AIT) is multifaceted, encompassing both clinical and quality‐of‐life improvements and cost‐effectiveness in the long term. Key mechanisms of allergen tolerance induced by AIT include changes in memory type allergen‐specific T‐ and B‐cell responses towards a regulatory phenotype with decreased Type 2 responses, suppression of allergen‐specific IgE and increased IgG1 and IgG4, decreased mast cell and eosinophil numbers in allergic tissues and increased activation thresholds. The potential of novel patient enrolment strategies for AIT is taking into account recent advances in biomarkers discoveries, molecular allergy diagnostics and mobile health applications contributing to a personalized approach enhancement that can increase AIT efficacy and compliance. Artificial intelligence can help manage and interpret complex and heterogeneous data, including big data from omics and non‐omics research, potentially predict disease subtypes, identify biomarkers and monitor patient responses to AIT. Novel AIT preparations, such as synthetic compounds, innovative carrier systems and adjuvants, are also of great promise. Advances in clinical trial models, including adaptive, complex and hybrid designs as well as real‐world evidence, allow more flexibility and cost reduction. The analyses of AIT cost‐effectiveness show a clear long‐term advantage compared to pharmacotherapy. Important research questions, such as defining clinical endpoints, biomarkers of patient selection and efficacy, mechanisms and the modulation of the placebo effect and alternatives to conventional field trials, including allergen exposure chamber studies are still to be elucidated. This review demonstrates that AIT is still in its growth phase and shows immense development prospects.

12 June 2020 in Allergy
Verified
Journal Article
Closed access
PDF file
OPOliver Pfaar
Oliver Pfaar
LKLudger Klimek
Ludger Klimek
MJMarek Jutel
Marek Jutel
CACezmi A. Akdis
Cezmi A. Akdis
JBJean Bousquet
Jean Bousquet
SUS Untersmayr
S Untersmayr

16 March 2020 in Journal of Medical Internet Research
Verified
Journal Article
Open access
MFMarco Di Fraia
Marco Di Fraia
STSalvatore Tripodi
Salvatore Tripodi
SAStefania Arasi
Stefania Arasi
SDStephanie Dramburg
Stephanie Dramburg
SCSveva Castelli
Sveva Castelli
PMPaolo Maria Matricardi
Paolo Maria Matricardi
Background: Complete diagnosis and therapy of seasonal allergic rhinoconjunctivitis require evidence that exposure to the sensitizing pollen triggers allergic symptoms. Electronic clinical diaries, by recording disease severity scores and pollen exposure, can demonstrate this association. However, patients who spontaneously download an e-diary app show very low adherence to their recording. Objective: The objective of our study was to assess adherence of patients with seasonal allergic rhinitis to symptom recording via e-diary explicitly prescribed by an allergist within a blended care approach. Methods: The @IT-2020 project is investigating the diagnostic synergy of mobile health and molecular allergology in patients with seasonal allergic rhinitis. In the pilot phase of the study, we recruited Italian children (Rome, Italy) and adults (Pordenone, Italy) with seasonal allergic rhinitis and instructed them to record their symptoms, medication intake, and general conditions daily through a mobile app (Allergy.Monitor) during the relevant pollen season. Results: Overall, we recruited 101 Italian children (Rome) and 93 adults (Pordenone) with seasonal allergic rhinitis. Adherence to device use slowly declined during monitoring in 3 phases: phase A: first week, ≥1267/1358, 90%; phase B: second to sixth week, 4992/5884, 80% to 90%; and phase C: seventh week onward, 2063/2606, 70% to 80%. At the individual level, the adherence assessed in the second and third weeks of recording predicted with enough confidence (Rome: Spearman ρ=0.75; P<.001; Pordenone: ρ=0.81; P<.001) the overall patient adherence to recording and was inversely related to postponed reporting (ρ=–0.55; P<.001; in both centers). Recording adherence was significantly higher during the peak grass pollen season in Rome, but not in Pordenone. Conclusions: Adherence to daily recording in an e-diary, prescribed and motivated by an allergist in a blended care setting, was very high. This observation supports the use of e-diaries in addition to face-to-face visits for diagnosis and treatment of seasonal allergic rhinitis and deserves further investigation in real-life contexts.

3 September 2018 in Clinical & Experimental Allergy
Verified
Journal Article
Closed access
PDF file
MFMarco Di Fraia
Marco Di Fraia
SAStefania Arasi
Stefania Arasi
SCSveva Castelli
Sveva Castelli
SDStephanie Dramburg
Stephanie Dramburg
EPEkaterina Potapova
Ekaterina Potapova
PMPaolo Maria Matricardi
Paolo Maria Matricardi